A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0-3.0) plus

Project: Other project

StatusFinished
Effective start/end date8/19/158/18/17

Funding

  • Boehringer Ingelheim Pharmaceuticals: $7,243.00